Integrated network pharmacology and molecular docking to investigate the potential mechanism of Tufuling on Alzheimer's disease.

OBJECTIVE

This study aimed to investigate the mechanism of Tu Fu Ling in treating Alzheimer's disease (AD) using network pharmacology and molecular docking.

METHODS

The TCMSP and Swiss target prediction databases were utilized to confirm the active components of Tu Fu Ling and their corresponding targets, with target gene names converted using the UniProt database. Genes related to AD were collected from DisGeNET, GeneCards, and the Open Target Platform databases. Common target genes between the disease and the drug were obtained using Venny 2.1 tools and visualized using Cytoscape software. Protein-protein interaction (PPI) data were further analyzed to determine correlations between common target genes, and GO and KEGG pathway enrichment analyses were performed for intersecting genes. Finally, PYmol, AutoDock Tool, Discovery Studio 2020, and PyRx software were used for preliminary computer virtual verification and visualization of active drug ingredients and target proteins.

RESULTS

Nine active ingredients meeting the screening criteria yielded a total of 168 genes after removing duplicates. A total of 3833 target genes were collected, with 129 overlapping target genes identified. GO enrichment analysis identified 643 biological processes, 82 cellular components, and 147 molecular functions. KEGG pathway enrichment analysis also revealed a pathway closely related to AD (hsa05010: Alzheimer's disease). In molecular docking analysis, the binding affinity between the 9 active ingredients and 10 core targets ranged from -3.5 to -12.3 kcal/mol, indicating strong binding.

CONCLUSION

This study preliminarily verified the combination of Tu Fu Ling's screened active ingredient and the calculated core target, suggesting a potential mechanism of action to improve the symptoms of AD patients through multi-target and multi-pathway approaches. This provides a valuable reference for further exploration of the pharmacological mechanism of AD and the formulation of drug therapy.